FLT3 and acute myeloid leukemia: Gilterinitib has been approved by the United States Food and Drug Administration (FDA) in the management of AML, following the promising results of the open-label, multicenter, randomized phase III ADMIRAL study (NCT02421939), where gilteritinib was compared with salvage chemotherapy in relapsed/refractory FLT3-mutated AML patients [8].